Top

Published in:

Open Access 01-12-2023 | Research

Meningiomas in patients with neurofibromatosis type 2 predominantly comprise ‘immunogenic subtype’ tumours characterised by macrophage infiltration

Authors: Yu Teranishi, Satoru Miyawaki, Masahiro Nakatochi, Atsushi Okano, Kenta Ohara, Hiroki Hongo, Daiichiro Ishigami, Yu Sakai, Daisuke Shimada, Shunsaku Takayanagi, Masako Ikemura, Daisuke Komura, Hiroto Katoh, Jun Mitsui, Shinichi Morishita, Tetsuo Ushiku, Shumpei Ishikawa, Hirofumi Nakatomi, Nobuhito Saito

Published in: Acta Neuropathologica Communications | Issue 1/2023

Abstract

Although recent molecular analyses revealed that sporadic meningiomas have various genetic, epigenetic, and transcriptomic profiles, meningioma in patients with neurofibromatosis type 2 (NF2) have not been fully elucidated. This study investigated meningiomas' clinical, histological, and molecular characteristics in NF2 patients. A long-term retrospective follow-up (13.5 ± 5.5 years) study involving total 159 meningiomas in 37 patients with NF2 was performed. Their characteristics were assessed using immunohistochemistry (IHC), bulk-RNA sequencing, and copy number analysis. All variables of meningiomas in patients with NF2 were compared with those in 189 sporadic NF2-altered meningiomas in 189 patients. Most meningiomas in NF2 patients were stable, and the mean annual growth rate was 1.0 ± 1.8 cm³/year. Twenty-eight meningiomas (17.6%) in 25 patients (43.1%) were resected during the follow-up period. WHO grade I meningiomas in patients with NF2 were more frequent than in sporadic NF2-altered meningiomas (92.9% vs. 80.9%). Transcriptomic analysis for patients with NF2/sporadic NF2-altered WHO grade I meningiomas (n = 14 vs. 15, respectively) showed that tumours in NF2 patients still had a higher immune response and immune cell infiltration than sporadic NF2-altered meningiomas. Furthermore, RNA-seq/IHC-derived immunophenotyping corroborated this enhanced immune response by identifying myeloid cell infiltration, particularly in macrophages. Clinical, histological, and transcriptomic analyses of meningiomas in patients with NF2 demonstrated that meningiomas in NF2 patients showed less aggressive behaviour than sporadic NF2-altered meningiomas and elicited a marked immune response by identifying myeloid cell infiltration, particularly of macrophages.

Available only for authorised users

Evans DGR (2009) Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 4:16CrossRefPubMedPubMedCentral

Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z et al (2009) Neurofibromatosis type 2. Lancet 373:1974–1986CrossRefPubMedPubMedCentral

Smith MJ, Higgs JE, Bowers NL, Halliday D, Paterson J, Gillespie J et al (2011) Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutation: clear positional effect of mutations, absence of female severity effect on age at onset. J Med Genet 48(4):261–265CrossRefPubMed

Baser ME, Friedman JM, Aeschliman D, Joe H, Wallace AJ, Ramsden RT et al (2002) Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 71:715–723CrossRefPubMedPubMedCentral

Hexter A, Jones A, Joe H, Heap L, Smith MJ, Wallace AJ et al (2015) Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. J Med Genet 52:699–705CrossRefPubMed

Lewis D, Donofrio CA, O’Leary C, Li KL, Zhu X, Williams R et al (2020) The microenvironment in sporadic and neurofibromatosis type II–related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study. J Neurosurg 134(5):1419–1429CrossRefPubMed

Samii M, Matthies C, Tatagiba M (1997) Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 40:696–705CrossRefPubMed

Brackmann DE, Fayad JN, Slattery WH, Friedman RA, Day JD, Hitselberger WE et al (2001) Early proactive management of vestibular schwannomas in neurofibromatosis type 2. Neurosurgery 49:274–280PubMed

Peyre M, Goutagny S, Imbeaud S, Bozorg-Grayeli A, Felce M, Sterkers O et al (2011) Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2. Neuro Oncol 13(10):1125–1132CrossRefPubMedPubMedCentral

10.

Goutagny S, Kalamarides M (2010) Meningiomas and neurofibromatosis. J Neurooncol 99(3):341–347CrossRefPubMed

11.

Abi Jaoude S, Peyre M, Degos V, Goutagny S, Parfait B, Kalamarides M (2020) Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients. J Neurosurg 134(5):1377–1385CrossRefPubMed

12.

Goutagny S, Bah AB, Henin D, Parfait B, Grayeli AB, Sterkers O et al (2012) Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neuro Oncol 14(8):1090–1096CrossRefPubMedPubMedCentral

13.

Perry A, Giannini C, Raghavan R, Scheithauer BW, Banerjeee R, Margraf L et al (2001) Aggressive phenotypic and genotypic features in pediatric and NF2- associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 60(10):994–1003CrossRefPubMed

14.

Antinheimo J, Haapasalo H, Halite M, Tatagiba M, Thomas S, Brandis A et al (1997) Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. J Neurosurg 87:610–614CrossRefPubMed

15.

Clark VE, Erson-Omay EZ, Serin A, Yin A, Cotney J, Ozduman K et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339(6123):1077–1080CrossRefPubMedPubMedCentral

16.

Sahm F, Schrimpf D, Stichel D, Jones DTW, Heilscher T, Schefzyk S et al (2017) DNA methylation—based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18(5):682–694CrossRefPubMed

17.

Okano A, Miyawaki S, Hongo H, Dofuku S, Teranishi Y, Takayanagi S et al (2021) Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges. Sci Rep 11:6987CrossRefPubMedPubMedCentral

18.

Prager BC, Vasudevan HN, Dixit D, Bernatchez J, Wu Q, Wallace LC et al (2020) The meningioma enhancer landscape delineates novel subgroups and drives druggable dependencies. Cancer Discov 10(11):1722–1741CrossRefPubMedPubMedCentral

19.

Boetto J, Bielle F, Sanson M, Peyre M, Kalamarides M (2017) SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas. Neuro Oncol 19(3):345–351PubMedPubMedCentral

20.

Nassiri F, Liu J, Patil V, Mamatjan Y, Wang JZ, Hugh-White R et al (2021) A clinically applicable integrative molecular classification of meningiomas. Nature 597(7874):119–125CrossRefPubMed

21.

Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D et al (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841–846CrossRefPubMedPubMedCentral

22.

Smith MJ, Bowers NL, Bulman M, Gokhale C, Wallace AJ, King AT et al (2017) Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology 88:87–92CrossRefPubMedPubMedCentral

23.

Teranishi Y, Miyawaki S, Hongo H, Dofuku S, Okano A, Takayanagi S et al (2021) Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2. J Med Genet 58(10):701–711CrossRefPubMed

24.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545–15550CrossRefPubMedPubMedCentral

25.

Hanzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform 14:7CrossRef

26.

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y et al (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453–457CrossRefPubMedPubMedCentral

27.

Aran D, Zicheng Hu, Butte AJ (2017) xCell/digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18(1):220CrossRefPubMedPubMedCentral

28.

Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Garcia WT et al (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat commun 4:2612CrossRefPubMed

29.

Rapp C, Dettling S, Liu F, Ull AT, Warta R, Jungk C et al (2019) Cytotoxic T cells and their activation status are independent prognostic markers in meningiomas. Clin Cancer Res 25(17):5260–5270CrossRefPubMed

30.

Lee EJ, Kim JH, Park ES, Kim YH, Lee JK, Hong SH et al (2017) A novel weighted scoring system for estimating the risk of rapid growth in untreated intracranial meningiomas. J Neurosurg 127(5):971–980CrossRefPubMed

31.

Yeung J, Yaghoobi V, Miyagishima D, Vesely MD, Zhang T, Badri T et al (2021) Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro Oncol 23(11):1922–1935CrossRefPubMedPubMedCentral

32.

Blume C, Dogan D, Schweizer L, Peyre M, Doll S, Picard D et al (2021) Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion. BioRxiv 05(11):443369. https://doi.org/10.1101/2021.05.11.443369CrossRef

33.

Choudhury A, Magill ST, Eaton CD, Prager BC, Chen WC, Cady MA et al (2022) Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet 54:649–659CrossRefPubMedPubMedCentral

34.

Wang AZ, Bowman-Kirigin JA, Desai R, Kang LI, Patel PR, Patel B et al (2022) Single-cell profiling of human dura and meningioma reveals cellular meningeal landscape and insights into meningioma immune response. Genome Med 14:49CrossRefPubMedPubMedCentral

35.

Williams EA, Santagata S, Wakimoto H, Shankar GM, Barker FG, Sharaf R et al (2020) Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun 8:171CrossRefPubMedPubMedCentral

Title: Meningiomas in patients with neurofibromatosis type 2 predominantly comprise ‘immunogenic subtype’ tumours characterised by macrophage infiltration
Authors: Yu Teranishi
Satoru Miyawaki
Masahiro Nakatochi
Atsushi Okano
Kenta Ohara
Hiroki Hongo
Daiichiro Ishigami
Yu Sakai
Daisuke Shimada
Shunsaku Takayanagi
Masako Ikemura
Daisuke Komura
Hiroto Katoh
Jun Mitsui
Shinichi Morishita
Tetsuo Ushiku
Shumpei Ishikawa
Hirofumi Nakatomi
Nobuhito Saito
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: Acta Neuropathologica Communications / Issue 1/2023
Electronic ISSN: 2051-5960
DOI: https://doi.org/10.1186/s40478-023-01645-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Meningiomas in patients with neurofibromatosis type 2 predominantly comprise ‘immunogenic subtype’ tumours characterised by macrophage infiltration

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Deep histopathology genotype–phenotype analysis of focal cortical dysplasia type II differentiates between the GATOR1-altered autophagocytic subtype IIa and MTOR-altered migration deficient subtype IIb

Three dimensional evaluation of cerebrovascular density and branching in chronic traumatic encephalopathy

Low-intensity open-field blast exposure effects on neurovascular unit ultrastructure in mice

Tau in cerebrospinal fluid induces neuronal hyperexcitability and alters hippocampal theta oscillations

Tau seed amplification assay reveals relationship between seeding and pathological forms of tau in Alzheimer’s disease brain

Patients with sporadic FTLD exhibit similar increases in lysosomal proteins and storage material as patients with FTD due to GRN mutations